JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD

Rumah> Blog> Teva Pharmaceuticals and Syqe Healthcare Collaborate to Market Medical Cannabis Inhalers

Teva Pharmaceuticals and Syqe Healthcare Collaborate to Market Medical Cannabis Inhalers

June 09, 2024

Teva, the Israeli pharmaceutical company, and Syqe Medical, based in Tel Aviv, have signed a distribution cooperation agreement to market medical marijuana inhalers, making it the world's first.

Under the agreement, Teva will become the exclusive marketer and distributor of medical marijuana inhalers developed by Syqe in Israel. According to Syqe, the agreement marks the first time that a large global pharmaceutical company has agreed to market medical cannabis products.

Under the terms of the agreement between Syqe and Teva, the Syqe inhaler is expected to be approved by the Israeli Ministry of Health for home use by next year. With the approval of the Israeli Ministry of Health, the Syqe inhaler has been in use at the Rambam Hospital in Haifa for more than a year, and the hospital has thus become the first hospital in the world to use cannabis as a standard drug treatment.

Teva Pharmaceuticals and Syqe Healthcare Collaborate to Market Medical Cannabis Inhalers

The value of the international medical cannabis market is expected to be approximately $20 billion over the next decade. About 1% of the world's population may use medical marijuana for the rest of their lives.

"Teva is entering the medical marijuana market with a strong commitment to those suffering from the disease, which is our core therapeutic area," said Avinoam Sapir, CEO of Teva, Israel. The advanced technology and groundbreaking medical equipment developed by Syqe is in full compliance with Teva's strategy.” Sapir is also the Director of Teva Africa and Middle East Marketing and Director of Innovation for Emerging Markets.

Sapir said Teva will fund or collaborate with local start-ups and Israeli pioneering projects to acquire innovative technology and advanced medical equipment. The newly signed agreement is consistent with Teva's investment strategies.

Hubungi Kami

Author:

Mr. Jarvis

Phone/WhatsApp:

+86 15252670022

Produk popular
You may also like
Related Categories

E-mel kepada pembekal ini

Subjek:
E-mel:
Mesej:

Your message must be betwwen 20-8000 characters

Hantar pertanyaan

Tel:86-0523-83320899

Fax:86-0523-83320899

Telefon mudah alih:+86 15252670022Contact me with Whatsapp

E-mel:tianhe@skyplant.cn

Alamat:Nanshan Road, Zhaoyang Industrial, Xinghua, Taizhou, Jiangsu

Tapak Mudah Alih

Rumah

Product

Whatsapp

Tentang kita

Siasatan

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Menghantar